DeepNovoV2: Better de novo peptide sequencing with deep learning

preprint · arXiv · 2019

preprint · arXiv · 2019. Rui Qiao et al. Personalized cancer vaccines are envisioned as the next generation rational cancer immunotherapy. The key…
Date 2019-04-17
Type preprint
Venue arXiv
Publisher arXiv
Contribution algorithm
DOI 10.48550/arXiv.1904.08514
Citations (OpenAlex) 15

Abstract

Personalized cancer vaccines are envisioned as the next generation rational cancer immunotherapy. The key step in developing personalized therapeutic cancer vaccines is to identify tumor-specific neoantigens that are on the surface of tumor cells. A promising method for this is through de novo peptide sequencing from mass spectrometry data. In this paper we introduce DeepNovoV2, the state-of-the-art model for peptide sequencing. In DeepNovoV2, a spectrum is directly represented as a set of (m/z, intensity) pairs, therefore it does not suffer from the accuracy-speed/memory trade-off problem. The model combines an order invariant network structure (T-Net) and recurrent neural networks and provides a complete end-to-end training and prediction framework to sequence patterns of peptides. Our experiments on a wide variety of data from different species show that DeepNovoV2 outperforms previous state-of-the-art methods, achieving 13.01-23.95\% higher accuracy at the peptide level.

Authors

  1. Rui Qiao · Bioinformatics Solutions Inc., University of Waterloo
  2. Ngoc Hieu Tran · Bioinformatics Solutions Inc., University of Waterloo
  3. Lei Xin · Bioinformatics Solutions Inc.
  4. Baozhen Shan · Bioinformatics Solutions Inc.
  5. Ming Li · Bioinformatics Solutions Inc., Peng Cheng Laboratory, University of Waterloo, University of Western Ontario
  6. Ali Ghodsi · University of Waterloo

Methods and tools

Cited by (5)

Seen in the charts

Back to the full map

Back to top